Anti-ADDL antibodies and uses thereof

US8889138B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Northwestern University · US

Inventors

• Paul Acton · Newbury Park, US
• Zhiqiang An · Houston, US
• Andrew J. Bett · Lansdale, US
• Robert Breese · Quakertown, US
• Elizabeth Chen Dodson · Souderton, US
• Gene Kinney
• William L. Klein · Nutley, US
• Mary P. Lambert · Glenview, US
• Xiaoping Liang · Collegeville, US
• Paul J. Shughrue · Johnstown, US
• William Strohl · Bound Brook, US
• Kirsten L. Viola · Lake Forest, US
• Lei Chang · Heverlee, BE

Key dates

• Filing date: Oct 11, 2010
• Grant date: Nov 18, 2014
• Expiry date: Sep 19, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2821
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.